Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, F?rkkil? A, Fuh K, Neel BG, Bowtell DD. Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026 Jun; 26(6):452-471.
-
Wu D, Burstyn I, Thompson WJ, Qian J, Mundt KA. Recall bias in population-based case-control studies of ovarian cancer and genital talcum powder use: potential impact and quantitative bias analysis. BMC Med Res Methodol. 2026 Mar 23; 26(1).
-
Du M, Peng P, Cao D, Cheng N, Yao L, Sun Y, Li J, Zhang H, Lou G, Tang J, Wang D, Wang Y, Zhang G, Xiang Y. Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study. J Ovarian Res. 2026 Jan 26; 19(1).
-
Kim J, Shin DW, Lee J, Lee MJ, Yu YG, Lee DH, Kang TH. Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer. ACS Synth Biol. 2026 01 16; 15(1):309-320.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 10; 12(39):e01014.
-
Sipes J, Zha D, Rayamajhi S, Bantis LE, Madan R, Mitra A, Puri RV, Rahman MM, Ahmmed F, Pathak HB, Russo A, Sardiu M, Isenberg BC, Cain BP, Coppeta J, Galhenage PM, Pathania S, David SM, Burdette JE, Godwin AK. Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles. Cancer Res Commun. 2025 Aug 01; 5(8):1266-1281.
-
You B, Anderson C, Cecere SC, Carrot A, Myers T, Heitz F, Sharma S, Sel?ukbiricik F, Aghajanian C, Fernebro J, Blank S, Laudani ME, Thaker PH, Yunokawa M, Willmott L, Lisyanskaya A, Hegg R, He Y, Landen C, Lin YG, Alarc?n J, Moore KN. Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial. Gynecol Oncol. 2025 06; 197:66-73.
-
Herzog TJ, Liao JB, Finkelstein K, Willmott L, Duan W, Moroney JW, Buscema J, Campbell-Simms K, Yue Y, Zweizig S, Liu J, Wang X, Zang RY, Yin R, O'Malley DM, Wu L. An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 03; 194:145-152.
-
Goh KY, Tham SC, Cheng TY, Nadarajah R, Goh RCH, Wong SL, Ho TH, Chew GK, Tan AWK, Rajesh H, Chua HL, Yong TT, Yu SL, Kang JM, Lau KW, Tay AZE, Mantoo S, Busmanis I, Chew SH, Lim TYK, Wong WL, Ng QJ, Wang J, Tay SK, Cheok CF, Lim DW, Lim EH. Cell Migration in Endometriosis Responds to Omentum-Derived Molecular Cues Similar to Ovarian Cancer. Int J Mol Sci. 2025 Feb 20; 26(5).